UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY
To promote professional and public awareness of NET throughout the UK and Ireland with the aim of optimising patient care and outcomes. This will be achieved through research, education, communications and patient and professional advocacy, working with other professional bodies, charities, patient groups and governments.
Objects
THE SOCIETY'S OBJECTS ARE TO PROMOTE FOR THE PUBLIC BENEFIT RESEARCH, EDUCATION AND IMPROVED QUALITY OF CLINICAL PRACTICE IN NEUROENDOCRINE TUMOURS BY THE ORGANISATION OF CONFERENCES, TRAINING COURSES AND PUBLICATIONS, BY RAISING PUBLIC AWARENESS, LIAISON WITH NATIONAL AND INTERNATIONAL LEGISLATORS, AND BY ANY OTHER APPROPRIATE MEANS. THE SOCIETY AIMS TO IMPROVE THE DIAGNOSIS, THERAPY AND SURVIVORSHIP OF PATIENTS WITH NEUROENDOCRINE TUMOURS WITHIN A NATIONAL MULTIDISCIPLINARY AND SCIENTIFIC CONTEXT.
Financial health, per its FY2025 accounts
The accounts state that the charity ended the year with £168,917 in unrestricted funds, which the trustees deem sufficient to cover management, administration, and support costs. The charity reported a net income of £6,458 for the year, having spent £121,502 against income of £127,960. The reserves policy targets a minimum of two years' expenditure to ensure financial viability.
What the accounts disclose
“Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions.” — page 6
“That level is currently deemed to be one that equates to a minimum of two years’ expenditure.”
Policies the charity declares
- Conflicting interests
- Engaging external speakers at charity events policy and procedures
- Financial reserves policy and procedures
- Internal charity financial controls policy and procedures
- Social media policy and procedures
- Trustee conflicts of interest policy and procedures
- Trustee expenses policy and procedures
Trustees
- David Mark Pritchard
- Dr Alia Munir
- Dr Rajaventhan Srirajaskanthan
- Dr Tahir Hussain Shah
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/08/2025 | £128k | £122k |
| 31/08/2024 | £137k | £122k |
| 31/08/2023 | £58k | £70k |
| 31/08/2022 | £98k | £86k |
| 31/08/2021 | £95k | £86k |
Common questions
Is UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY financially healthy?
Per its FY2025 accounts: The accounts state that the charity ended the year with £168,917 in unrestricted funds, which the trustees deem sufficient to cover management, administration, and support costs. The charity reported a net income of £6,458 for the year, having spent £121,502 against income of £127,960. The reserves policy targets a minimum of two years' expenditure to ensure financial viability. Its FY2025 accounts were independently examined.